Summary In 31 patients with carcinoma of the breast the phenotype and activation status of tumour infiltrating lymphocytes (TILs) was analysed by flow cytometry. The predominant cells, in all patients, were T lymphocytes and in the majority of cases CD8 + (cytotoxic/suppressor) T lymphocytes were present in greater numbers than CD4+ (helper) T lymphocytes. There was no relationship between the degree of lymphocytic infiltration and either tumour stage or grade but there appeared to be an inverse correlation with the levels of oestrogen receptor (ER) in the tumour (P<0.01). Both populations of T cells had significantly higher numbers of cells carrying HLA DR (class II major histocompatibility antigen) than the equivalent populations in peripheral blood from the same patient group (P<0.001). The transferrin receptor was found on similar numbers of CD8+ T cells in peripheral blood and among the tumour infiltrating lymphocytes while more of the CD4+ T cells infiltrating the tumour were found to carry this receptor (P=0.034). The Tac (CD25) antigen was also on similar numbers of CD8 + T cells from both peripheral blood and the tumour but was on fewer of the CD4+ T cells in the tumour with respect to peripheral blood (P = 0.029). In both TILs and blood lymphocytes, the Tac antigen was consistently present on greater numbers of CD4+ T lymphocytes than on the CD8+ T lymphocytes (P<0.001) and as this is a component of the interleukin 2 (IL-2) receptor this may be of relevance to the use of IL-2 in TIL cancer therapy.
Tumour infiltrating lymphocytes (TILs) and in particular their response to interleukin 2 (IL-2), have attracted considerable interest in recent years because of their possible therapeutic potential (for reviews see Oldham et al., 1989; Rosenberg et al., 1989) . It was first suggested by MacCarty (1922) , on the basis of his observations on patients with gastric carcinoma, that lymphoid infiltration in breast tumours was a sign of host resistance. This appeared to be supported by the study of medullary carcinoma, which often has a marked lymphocytic infiltrate and has a particularly good prognosis (Moore & Foote, 1949) . However, as Richardson (1956) pointed out, medullary tumours have a better prognosis due to their poor stroma formation and reduced ability to form metastases even when the lymphocytic infiltrate is not present. Black (1955) and then Berg (1959) sug- gested that mononuclear cells observed within other types of breast carcinoma on histological section related to increased survival and represented host resistance. These early studies noted merely the presence or absence of lymphocytes within the tumour and related this to long-term survival but were unable to gain much information about the cell types involved.
Studies utilising the ability of T cells to rosette sheep red blood cells showed that T cells were the major component of the lymphocytic infiltrate (Eremin et al., 1981; Vose et al., 1981; Eremin et al., 1982) (Whitwell et al., 1984; Gotlinger et al., 1985; Horny & Horst, 1986; Ben Ezra & Sheibani, 1987; Underwood et al., 1987; von Kleist et al., 1987; Zuk & Walker, 1987) , others showed a predominance of CD8 + T cells (Giorno, 1983; Bhan & des Marais, 1983;  Correspondence: A.M. Campbell. Received 22 March 1990; and in revised form 13 July 1990. Rowe & Beverly, 1984; Hurliman & Saraga, 1985; Bilik et al., 1989) . Taking solid tumours as a whole, most groups have found CD8 + T cells to be in the majority (Itoh et al., 1986; Rabinowich et al., 1987; Heo et al., 1987; Belledegrun et al., 1988; Rosenberg et al., 1988; Durie et al., 1990 Tumour samples were obtained aseptically at the time of operation then the main bulk of each tumour was sent for routine histology and the assay of tumour oestrogen receptors (ER). The latter was performed using the ligand binding method. After trimming away any fat, the tumour was divided and one portion stored dry in liquid nitrogen. The rest of the tumour was mechanically disaggregated using a scalpel and needle to tease apart the sample and release the cells into suspension. The resultant cell suspension was harvested, washed, and stored in liquid nitrogen in a freezing medium consisting of 10% dimethylsulphoxide (DMSO) and 90% fetal calf serum (FCS). The more fibrous tumours, which did not disaggregate well and yielded poor cell suspensions, were subjected to digestion overnight with collagenase (Slocum et al., 1981; Vose, 1981; Rios et al., 1983) . The resultant cell suspension was washed and stored in freezing medium in liquid nitrogen.
The peripheral blood, which had been collected in an EDTA coated tube, was diluted with an equal volume of RPMI 1640 and layered over Ficoll-Hypaque. The preparation was centrifuged at 500 g for 20 min to allow density separation of the leucocytes. The layer containing the lymphocytes was then harvested, washed and stored in freezing medium in liquid nitrogen.
Preparation was carried out as soon as possible after receipt of the samples to minimise turnover of membrane receptors. Surface marker analysis was performed only on cells spilled mechanically from the tumours because the lengthy incubation in collagenase might allow changes to occur in the membrane markers (Whiteside et al., 1986; Miescher et al., 1988) . Incubation was carried out in the dark to prevent bleaching and on ice, in the presence of 0.02% w/v sodium azide, to prevent capping and internalisation of the antibody-antigen complex. Antibodies (Becton Dickinson, Oxford, UK) were conjugated with either fluoroisothiocyanate (FITC) or phycoerythrin (PE) which emit green and orange fluorescence respectively (Table I) . After incubation with the fluorescent antibodies the cells were washed and resuspended in filtered PBS. Propidium iodide was added to each tube to a final concentration of 2figml1' to allow the identification and exclusion of dead cells from the analysis. The cell samples were then run through the flow cytometer and 5,000 live cells were analysed for each sample.
Analysis
An irrelevant antibody control (goat anti-mouse IgG FITC and goat anti-mouse IgG PE) was used to set the analysis gates to exclude non-specific binding. Leucogate (Table I) , an antibody preparation differentially staining lymphocytes, monocytes and neutrophils, was used to measure the proportion of lymphocytes in the sample being studied. This analysis was performed without any scatter gates which might have altered the proportions of the cells measured. Then, utilising the forward and side scatter (FSC and SSC) properties of lymphocytes in laser light, a gate was drawn around the lymphocytes to exclude tumour cells from further analysis of the tumour sample and monocytes and neutrophils from analysis of the peripheral blood samples. Phenotypic and activation marker analysis was performed using both the lymphocyte and live cell gates. Macrophages and monocytes were excluded by these gates but some NK cells fell within them. This accounts for the null cells (non-T cells, non-B cells) within peripheral blood.
The relative proportions of the phenotypic subsets were measured using four-quadrant analysis while activation markers were measured by isolating the phenotype under study on the instrument and using histogram analysis. The analysis gate for positive cells was based on the goat anti-mouse control for non-specific staining. Preparations of anti-Leu 4 FITC/anti-Leul2 PE and anti-Leu3a FITC/anti-Leu2a PE allowed the lymphocytes to be phenotyped as T cells, B cells, CD4+ (helper) T cells, or CD8+ (cytotoxic/suppressor) T cells.
The activation markers studied were HLA DR, the class II major histocompatibility antigen, Tac (CD-25) the 55 kDa component of the interleukin-2 receptor, and the transferrin receptor. Double staining techniques with PE conjugated phenotypic antibodies and FITC conjugated activation marker antibodies demonstrated the proportion of CD4 + T cells and CD8+ T cells bearing these markers.
Statistical analysis, where appropriate, was by the Wilcoxon signed rank test. Tumour grading was by the method of Bloom and Richardson (1957) .
Results
The patient group studied is shown in Table II . Nine of the tumours contained too few lymphocytes to permit study of their activation markers with four having too small an infiltrate even for phenotyping. The lymphocytic infiltrate ranged from less than 1% of the cells harvested to 83% with a mean of 10.5%. This did not correlate with tumour stage or histological grade but there was an inverse correlation between the severity of lymphocytic infiltration and the levels of ER in the tumour (P<0.01) (Figure 1 ). In line with the results of the majority of other groups, we found the tumour infiltrate to consist largely of T cells with only one tumour containing a significant number of B cells (Figure 2 ). This was also the tumour with the largest lymphocytic infiltrate but no trend was seen among the other tumours. When the T cells were further subdivided, the CD8+ population was found to predominate, though in seven tumours the CD4+ T cells were present in greater numbers (Figure 3) .
The CD4+/CD8+ ratio ranged from 0.2 to 2.1 with an average of 0.8, which was a reversal of that in peripheral blood, where the CD4+/CD8+ ratios ranged from 0.8 to 5.0 with an average of 1.7.
Among the activation markers, HLA DR (Figure 4 ) was present on many more of both CD8 + T cells (average 57%) Table II Patient data   Grade   II  III  III  II   II   I   II   II   I  II  II  I  III  III  Lobular   II   III   II   III   II   I   II   II   II   II   II   I   III  III   Stage   II   I  I  I   II   II   II   II   I   II   II   I  I  I  I   II   II   I   II   II   II   II   I   II  I  I   II (Figure 5 ), the numbers of CD8+ T cells within the tumour bearing this marker (average 39%) were not significantly higher than the numbers in blood (average 38%). This receptor was present on more of the CD4 + T cells in the tumour (average 48%) than in the blood (average 35%) (P= 0.034).
A different trend was observed with the Tac antigen ( Figure 6 ) which was present on similar numbers of CD8 + T cells in both the infiltrate (average 14%) and in blood (average 16%) but tended to be on fewer CD4+ T cells in the infiltrate (average 27.5%) than in blood (average 33%) (P = 0.029).
It is particularly noteworthy that this component of the I1-2 receptor was consistently found on more CD4 + T cells than CD8 + T cells in both tumour infiltrating and peripheral blood lymphocytes (P<0.001). Giorno (1983) , Rowe and Beverly (1984), Bilik et al. (1989) and others, although at odds with the findings of such groups as Horny and Horst (1986) , Underwood et al. (1987) (Edwards, 1985) Consistently greater numbers of CD4 + rather than CD8 + T cells bear this marker, whether in blood or in the tumour infiltrate. Tsudo et al. (1986) and Robb et al. (1987) have demonstrated that the 11-2 receptor has two components, one at 55 kDa, and the other, which carries the signal transduction mechanism, at 75 kDa (reviewed by Smith, 1989 qualitative, difference between the two cell types. This interpretation is supported by the finding that, in long-term 11-2 cultures, the CD4+ (helper) subpopulation appears to be selectively expanded over the CD8 + (cytotoxic/suppressor) population and thus the cells being returned to the patient as TIL therapy are predominantly of the helper phenotype Belldegrun et al., 1988 
